#LifeSciences #MedicalAffairs #GLP1 #ObesityCare #Pharma #Biopharma #HealthcareInnovation #ClinicalResearch #MedicalCommunications #AIInHealthcare To view or add a comment, sign in One month from today, stakeholders from across the wound care community will come together for an important conversation that could help shape the future of drug development
MK 677, by contrast, mimics ghrelinthe 'hunger hormone' that binds to growth hormone secretagogue receptors (GHS-R1a) in both the hypothalamus and pituitary
Manu Chakravarthy Roche's head of cardiovascular, renal and metabolism product development has said that the company believes this will help recruit and retain patients
This information helps your provider assess whether your technique needs correction and whether any dose adjustments are warranted
Looking forward to my next
Weight Loss as Preventive Care: Insurers are beginning to reimburse GLP-1s for obesity, recognizing its role in reducing long-term healthcare costs